Clin Mol Hepatol.
2018 Dec;24(4):351-357. 10.3350/cmh.2017.0063.
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
- Affiliations
-
- 1Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea. 20050101@kuh.ac.kr
- KMID: 2433297
- DOI: http://doi.org/10.3350/cmh.2017.0063
Abstract
- The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few side effects and no comorbidities in the general population. Until recently, ideal DAA regimens have not been available to patients with severe renal impairment and end-stage renal disease because there are limited data on the pharmacokinetics, safety, and efficacy of treatment in this unique population. In a hemodialysis context, identifying patients in need of treatment and preventing HCV transmission may also be a matter of concern. Recently published studies suggest that a combination of paritaprevir/ritonavir/ombitasvir and dasabuvir, elbasvir/grazoprevir, or glecaprevir/pibrentasvir successfully treats HCV infection in chronic kidney disease stage 4 or 5 patients with or without hemodialysis.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Kidney disease in patients with chronic liver disease
- 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
- Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”
- Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
- Toward a Functional Cure for Hepatitis B
